CSF2 and melanoma: Recently, final analysis of the OPTiM phase III trials comparing T-VEC versus GM-CSF treatment in 436 patients with unresectable stage III-IV melanoma, T-VEC was shown to improve long-term efficacy and was well tolerated with median OS for T-VEC treatment of 23.3 months and ORR of 31.5% [72].